Columbia Care Reports Fourth Quarter and Full Year 2022 Results
Columbia Care reported a record annual revenue of $511.6 million, marking an 11% increase year-over-year. The annual gross profit was $201.2 million, a 4% rise, while adjusted EBITDA reached $67.4 million, up 17%. Despite facing macroeconomic challenges, fourth-quarter revenues fell to $126.2 million, down 9.4% year-over-year. Key markets like New Jersey and Virginia continued to drive growth, contributing to an increased adjusted EBITDA margin of 13%. Ongoing operational adjustments aim to enhance cash flow generation in 2023.
- Record annual revenue of $511.6 million, up 11% YoY.
- Record gross profit of $201.2 million, a 4% YoY increase.
- Adjusted EBITDA of $67.4 million, reflecting a 17% YoY growth.
- Increased adjusted EBITDA margin by 60bps to 13%.
- Revenue growth driven by strategic presence in high-growth markets like New Jersey and Virginia.
- Fourth-quarter revenue declined by 9.4% YoY to $126.2 million.
- Gross profit decreased by 27.3% in Q4 2022 compared to Q4 2021.
- Decline in adjusted gross margin of 148bps to 42.4%.
- Sequential decline of 30% in wholesale revenue.
Record Annual Revenue of
Record Annual Gross Profit of
Record Annual Adjusted EBITDA1 of
and Annual Adjusted EBITDA Margin1 of
“Columbia Care achieved record financial results again in 2022, as we continued to build scale and optimize our portfolio of assets within our strategically diverse retail footprint. Despite cyclicality in the fourth quarter coinciding with ongoing macroeconomic headwinds that impacted both the consumer, and in particular, wholesale market pricing, topline revenue grew to more than
Vita continued, “We are focusing our footprint on those markets that can drive the most value for our patients, customers, and shareholders – and reducing exposure in markets that do not contribute to the bottom line. The ongoing operational and financial reprioritization of resources we began implementing in the fourth quarter of 2022, which included a targeted corporate restructuring, multiple cost-reduction measures, several non-core asset divestitures, implementing improvements in cultivation and manufacturing quality and efficiency, and optimizing our liquidity position, will provide a pathway to free cash flow generation in 2023. We are confident in the embedded growth in our strategic footprint and in the expected impact of the improvements we are making to influence our profitability, cash flow and liquidity position.”
Full Year 2022 U.S. GAAP Financial Highlights (in $ thousands, excl. margin items): |
|||||||||||
|
Year Ended |
|
|||||||||
|
|
2022 |
|
|
2021 |
|
% YoY |
||||
Revenue |
$ |
511,578 |
|
$ |
460,080 |
|
11.2 |
% |
|||
Gross Profit |
$ |
201,211 |
|
$ |
194,015 |
|
3.7 |
% |
|||
Adj. Gross Profit[1,2] |
$ |
216,657 |
|
$ |
201,678 |
|
7.4 |
% |
|||
Adj. Gross Margin[1,2] |
|
42.4 |
% |
|
43.8 |
% |
-148 bps |
||||
Adj. EBITDA[1,2] |
$ |
67,376 |
|
$ |
57,852 |
|
16.5 |
% |
Fourth Quarter 2022 U.S. GAAP Financial Highlights (in $ thousands, excl. margin items): |
||||||||||||||||||
|
Q4 2022 |
Q3 2022 |
Q4 2021 |
% QoQ |
% YoY |
|||||||||||||
Revenue |
$ |
126,187 |
|
$ |
132,733 |
|
$ |
139,276 |
|
-4.9 |
% |
-9.4 |
% |
|||||
Gross Profit |
$ |
41,601 |
|
$ |
52,113 |
|
$ |
57,253 |
|
-20.2 |
% |
-27.3 |
% |
|||||
Adj. Gross Profit[1,2] |
$ |
47,182 |
|
$ |
56,870 |
|
$ |
61,995 |
|
-17.0 |
% |
-23.9 |
% |
|||||
Adj. Gross Margin[1,2] |
|
37.4 |
% |
|
42.8 |
% |
|
44.5 |
% |
-546 bps |
-712 bps |
|||||||
Adj. EBITDA[1,2] |
$ |
17,405 |
|
$ |
20,993 |
|
$ |
20,587 |
|
-17.1 |
% |
-15.5 |
% |
[1] Denotes a Non-GAAP measure. See “Non-GAAP Financial Measures” in this press release for more information regarding the Company’s use of non-GAAP financial measures, as well as Table 4 for reconciliation, where applicable. |
[2] Excludes |
Top 5 Markets by Revenue in Q4[3]:
Top 5 Markets by Adjusted EBITDA in Q4[3]:
[3]Markets are listed alphabetically |
Operational Highlights
Enhancing scale and optimizing best-in-class retail network:
-
Opened two Cannabist retail locations in
Virginia (Carytown & Williamsburg) at the end of Q4 2022, and closed 1 unprofitable retail location (CO) inDecember 2022 , ending the year with 84 active dispensaries -
As part of ongoing efficiency initiatives to enhance profitability announced in
January 2023 , the Company closed 3 additional unprofitable locations (2 inColorado , 1 inCalifornia ) and subsequently signed a definitive agreement to divest 1 unprofitable location inMissouri -
Also in Q1 2023, Company has opened 2 locations in
Virginia (Hampton &Colonial Heights ), bringing the current active retail location count to 83 -
Retail revenue remained flat in Q4 2022, with a slight improvement in same store sales, in spite of pricing headwinds; wholesale revenue declined
30% sequentially due to pricing pressure and intentional inventory management, which negatively impacted Q4 gross margin -
Company’s two active
New Jersey retail locations were among the top dispensaries in the portfolio; the thirdNew Jersey retail location is in development -
Virginia topline revenue grew nearly100% YoY, as new retail locations were added and the patient population continues to grow; Adj. EBITDA Margin for the year increased 19 percentage points over 2021 -
Additional dispensaries in development include 4 in
Virginia (scheduled to open in 2023), 1 inWest Virginia (expected to open this week), 1 inNew Jersey (expected to open in 2H 2023), and 1 currently in pursuit inMaryland
Proven cultivation expertise and execution:
-
In Q4 2022, the weighted average production cost per pound decreased by
8% across the portfolio - Enhanced production capabilities supported a shift in retail revenue product mix to include more concentrates, evidenced by a 5-percentage point increase in Q4 2022
- Continued progress on optimization of production planning, genetics selection, environmental controls and plant management across the cultivation portfolio
- Cultivation efficiency and standardization across markets continued to improve over prior performance, with multiple states seeing improved potency TAC% through strict adherence to standard operating procedures
Sustained momentum on branding initiatives at retail and product levels:
-
In
October 2022 , launched Hedy, a new cannabis-infused edibles brand, in six markets and in a variety of form factors and flavors; Hedy was developed using insights from our unique technological platforms, such as Forage, that help us better understand what our customers are seeking; Hedy is now available inArizona ,Colorado ,Delaware ,Illinois ,Massachusetts ,Missouri ,New York , andVirginia -
During Q4 2022, saw continued growth of
Stash Cash , the loyalty program and mobile application that launched in 14 markets in Q3 2022;Stash Cash provides Company with enhanced opportunity to engage and retain customers and patients, as well as insight into customer behaviors and preferences -
In Q1 2023, launched new line of formulated cannabis tablets, Press 2.0, in
Delaware ,Massachusetts ,New Jersey ,Virginia andWest Virginia -
In-house brands accounted for
61% of all flower sold atColumbia Care dispensaries in Q4 2022 and66% in FY 2022 -
There are now 33 Cannabist locations in the
U.S. with 5 additional openings planned in 2023
Capital Markets & Liquidity Highlights
-
The Company generated
of positive cash flow from operations in Q4 2022 and exited the year with$5.2 million in cash; Company spent approximately$48.2 million of cash in Q4 as a result of cost-savings, low CAPEX and improved working capital management, compared to$1.9 million of cash spend in Q3 2022 – a sequential improvement of$31.4 million $29.5 million -
Capital expenditures in Q4 were approximately
and$3.4 million for 2022$73.8 million -
On
March 13, 2023 , Company signed definitive agreement to divest interests in theMissouri market for approximately ;$7 million Missouri market generated in EBITDA loss in 2022$1 million -
On
March 28, 2023 , Company exercised its unilateral right to extend the maturity date of its13% senior secured notes in the amount of , originally due$38.2 million May 14, 2023 , toMay 14, 2024 ; Company has no debt maturities prior to that date other than approximately convertible note in$5.6 million December 2023 -
The corporate restructuring initiatives announced in
January 2023 , which reduced or exited cultivation operations in 6 markets, closed 4 unprofitable retail stores inColorado andCalifornia , and eliminated approximately25% of our corporate positions, are expected to generate a net in annualized savings$35 million -
Company has exited several markets and assets that were not accretive to positive cash flow, including closing its CBD and European business and selling its assets in
Puerto Rico , which when combined with recent exit ofMissouri , will generate an incremental savings of approximately annually going forward$3 million
Conference Call and Webcast Details
The Company will host a conference call on
To access the live conference call via telephone, participants must pre-register at https://register.vevent.com/register/BIe13a43cb0fb742c3b2fd08064bace8a8. After registering, instructions will be shared on how to join the call for those who wish to dial in. A live audio webcast of the call will also be available in the Investor Relations section of the Company's website at https://investors.columbia.care/ or at https://edge.media-server.com/mmc/p/9ed8sm24.
A replay of the audio webcast will be available in the Investor Relations section of the Company’s website approximately 2 hours after completion of the call and will be archived for 30 days.
About
Non-GAAP Financial Measures
In this press release,
With respect to non-GAAP financial measures, the Company defines EBITDA as net income (loss) before (i) depreciation and amortization; (ii) income taxes; and (iii) interest expense and debt amortization. Adjusted EBITDA is defined as EBITDA before (i) share-based compensation expense; (ii) goodwill and intangible impairment, (iii) adjustments for acquisition and other non-core costs; (iv) gain on remeasurement of contingent consideration, net, (v) fair value changes on derivative liabilities; and (vi) fair value mark-up for acquired inventory. Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Revenue. Adjusted Gross Profit is defined as gross profit before the fair mark-up for acquired inventory. Adjusted Gross Margin is defined as gross margin before the fair mark-up for acquired inventory.
The Company views these non-GAAP financial measures as a means to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results and comparison to competitors’ operating results. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to the corresponding GAAP financial measure, may provide a more complete understanding of factors and trends affecting the Company’s business. The determination of the amounts that are excluded from these non-GAAP financial measures are a matter of management judgment and depend upon, among other factors, the nature of the underlying expense or income amounts. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety.
Reconciliations of non-GAAP financial measures to their nearest comparable GAAP measures are included in this press release and a further discussion of some of these items will be contained in our annual report on Form 10-K.
Caution Concerning Forward-Looking Statements
This press release contains certain statements that constitute forward-looking information or forward looking statements within the meaning of applicable securities laws and reflect the Company’s current expectations regarding future events. Statements concerning Columbia Care’s objectives, goals, strategies, priorities, intentions, plans, beliefs, expectations and estimates, and the business, operations, financial performance and condition of the Company are forward-looking statements. The words “believe”, “expect”, “anticipate”, “estimate”, “intend”, “may”, “will”, “would”, “could”, “should”, “continue”, “plan”, “goal”, “objective”, and similar expressions and the negative of such expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward looking statements in this press release include, among others, statements related to: expectations related to growth, cost management and financial numbers including free cash flow, the
The Company has made assumptions with regard to its ability to execute on initiatives, which although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. Forward-looking information involves numerous assumptions, including assumptions on the satisfaction of the conditions precedent to the closing of the
Forward-looking statements may relate to future financial conditions, results of operations, plans, objectives, performance or business developments. These statements speak only as at the date they are made and are based on information currently available and on the then current expectations. Holders of securities of the Company are cautioned that forward-looking statements are not based on historical facts but instead are based on reasonable assumptions and estimates of management of the Company at the time they were provided or made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, as applicable, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Securityholders should review the risk factors discussed under “Risk Factors” in Columbia Care’s Form 10-K for the year ended
The purpose of forward-looking statements is to provide the reader with a description of management’s expectations, and such forward-looking statements may not be appropriate for any other purpose. In particular, but without limiting the foregoing, disclosure in this press release as well as statements regarding the Company’s objectives, plans and goals, including future operating results and economic performance may make reference to or involve forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. A number of factors could cause actual events, performance or results to differ materially from what is projected in the forward-looking statements. No undue reliance should be placed on forward-looking statements contained in this press release. Such forward-looking statements are made as of the date of this press release.
TABLE 1 - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
(in US $ thousands, except share and per share figures, unaudited) | |||||||||||||||
Three Months Ended |
Year Ended |
||||||||||||||
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Revenue | $ |
126,187 |
|
$ |
139,276 |
|
$ |
511,578 |
|
$ |
460,080 |
|
|||
Cost of sales |
|
(84,518 |
) |
|
(77,282 |
) |
|
(310,163 |
) |
|
(258,402 |
) |
|||
Cost of sales related to business combination fair value adjustments to inventory |
|
(68 |
) |
|
(4,741 |
) |
|
(204 |
) |
|
(7,663 |
) |
|||
Gross profit |
|
41,601 |
|
|
57,253 |
|
|
201,211 |
|
|
194,015 |
|
|||
Selling, general and administrative expenses |
|
(402,358 |
) |
|
(142,098 |
) |
|
(617,451 |
) |
|
(304,380 |
) |
|||
Loss from operations |
|
(360,757 |
) |
|
(84,845 |
) |
|
(416,240 |
) |
|
(110,365 |
) |
|||
Other income (expense), net |
|
22,618 |
|
|
30,952 |
|
|
(16,454 |
) |
|
(36,349 |
) |
|||
Income tax benefit (expense) |
|
37,122 |
|
|
(770 |
) |
|
11,213 |
|
|
(139 |
) |
|||
Net income (loss) |
|
(301,017 |
) |
|
(54,663 |
) |
|
(421,481 |
) |
|
(146,853 |
) |
|||
Net income (loss) attributable to non-controlling interests |
|
(907 |
) |
|
(1,388 |
) |
|
(5,476 |
) |
|
(3,756 |
) |
|||
Net income (loss) attributable to |
$ |
(300,110 |
) |
$ |
(53,275 |
) |
$ |
(416,005 |
) |
$ |
(143,097 |
) |
|||
Weighted average common shares outstanding - basic and diluted |
|
400,467,851 |
|
|
370,786,916 |
|
|
392,571,102 |
|
|
338,754,694 |
|
|||
Earnings per common share attributable to |
$ |
(0.75 |
) |
$ |
(0.14 |
) |
$ |
(1.06 |
) |
$ |
(0.42 |
) |
|||
TABLE 2 - CONDENSED CONSOLIDATED BALANCE SHEET (SELECT ITEMS) | |||||||||||
(in US $ thousands, unaudited) | |||||||||||
Three Months Ended | |||||||||||
Cash | $ |
48,154 |
$ |
50,023 |
$ |
81,440 |
$ |
168,424 |
|||
Total current assets |
|
237,177 |
|
208,515 |
|
256,110 |
|
323,883 |
|||
Property and equipment, net |
|
357,993 |
|
370,820 |
|
373,877 |
|
355,968 |
|||
Right of use assets |
|
219,895 |
|
259,655 |
|
254,849 |
|
250,413 |
|||
Total assets |
|
994,726 |
|
1,371,578 |
|
1,420,465 |
|
1,482,443 |
|||
Total current liabilities |
|
203,118 |
|
178,015 |
|
138,499 |
|
222,835 |
|||
Total liabilities |
|
787,823 |
|
870,701 |
|
892,496 |
|
952,743 |
|||
Total equity |
|
206,903 |
|
500,877 |
|
527,969 |
|
529,700 |
|||
Total liabilities and equity | $ |
994,726 |
$ |
1,371,578 |
$ |
1,420,465 |
$ |
1,482,443 |
|||
TABLE 3 - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||||||||
(in US $ thousands, unaudited) | |||||||||||||||
Three Months Ended | |||||||||||||||
Net cash provided by (used in) operating activities | $ |
5,152 |
|
$ |
(16,770 |
) |
$ |
(71,961 |
) |
$ |
(27,822 |
) |
|||
Net cash (used in) investment activities |
|
(3,369 |
) |
|
(14,276 |
) |
|
(28,127 |
) |
|
(29,555 |
) |
|||
Net cash provided by (used in) financing activities | $ |
(3,652 |
) |
$ |
(371 |
) |
$ |
13,454 |
|
$ |
144,253 |
|
|||
TABLE 4 - RECONCILIATION OF US GAAP TO NON-GAAP MEASURES | |||||||||||||||
(in US $ thousands, unaudited) | |||||||||||||||
Three Months Ended |
Year Ended |
||||||||||||||
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Net income (loss) | $ |
(301,017 |
) |
$ |
(54,663 |
) |
$ |
(421,481 |
) |
$ |
(146,853 |
) |
|||
Income tax (benefit) expense |
|
(37,122 |
) |
|
770 |
|
|
(11,213 |
) |
|
139 |
|
|||
Depreciation and amortization |
|
21,711 |
|
|
19,201 |
|
|
84,788 |
|
|
53,002 |
|
|||
Net interest and debt amortization |
|
14,035 |
|
|
11,328 |
|
|
52,542 |
|
|
30,014 |
|
|||
EBITDA (Non-GAAP) | $ |
(302,393 |
) |
$ |
(23,364 |
) |
$ |
(295,364 |
) |
$ |
(63,698 |
) |
|||
Share-based compensation | $ |
7,281 |
|
$ |
6,989 |
|
$ |
27,930 |
|
$ |
25,018 |
|
|||
|
340,121 |
|
|
72,328 |
|
|
340,121 |
|
|
72,328 |
|
||||
Adjustments for other acquisition and non-core costs |
|
10,310 |
|
|
(57,163 |
) |
|
38,407 |
|
|
29,827 |
|
|||
Gain on remeasurement of contingent consideration, net |
|
(37,362 |
) |
|
23,582 |
|
|
(37,362 |
) |
|
- |
|
|||
Fair value changes on derivative liabilities |
|
(620 |
) |
|
(6,526 |
) |
|
(6,560 |
) |
|
(13,286 |
) |
|||
Fair value mark-up for acquired inventory |
|
68 |
|
|
4,741 |
|
|
204 |
|
|
7,663 |
|
|||
Adjusted EBITDA (Non-GAAP) | $ |
17,405 |
|
$ |
20,587 |
|
$ |
67,376 |
|
$ |
57,852 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005431/en/
Investor
SVP, Capital Markets
ir@col-care.com
Media
VP, Communications
+1.978.662.2038
media@col-care.com
Source:
FAQ
What was Columbia Care's revenue for the full year 2022?
How much did Columbia Care's adjusted EBITDA increase in 2022?
What were the key challenges faced by Columbia Care in Q4 2022?
Which markets contributed to Columbia Care's growth in 2022?